Trial · NCT02802111
Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults
NCT02802111, Not applicable, Completed, Children's Hospital Los Angeles; results first posted 2020-10-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults. Trials, record NCT02802111. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02802111
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults
- NCT number
- NCT02802111
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- Children's Hospital Los Angeles
- Conditions
- Oxygen Consumption
- Interventions
- Albuterol, Levalbuterol
- First posted
- 2016-06-16
- Last updated
- 2020-10-28
- Results first posted
- 2020-10-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Oxygen Consumption | 0 to 60 minutes | Oxygen consumption will be measured following for up to 60 minutes beta agonist aerosol |
| Secondary | Heart Rate | 0 to 60 minutes | Vital signs including heart rate will be measured for up to 60 minutes following beta agonist |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Oxygen Consumption | 0 to 60 minutes | Healthy volunteers, median age 32 years. The population is 24 individuals they are randomized to which bronchodilator they received first. Half were randomized to Albuterol and half to levalbuterol but each subject received both medication. It is a matter of which they received first. There was a four hour wash out period between the first and second medication. | mls/kg/min | MEDIAN |
| SECONDARY | Heart Rate | 0 to 60 minutes | Healthy volunteers, median age 32 years. The population is 24 individuals they are randomized to which bronchodilator they received first. Half were randomized to Albuterol and half to levalbuterol but each subject received both medication. It is a matter of which they received first. There was a four hour wash out period between the first and second medication. | beats per minute | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Oxygen Consumption | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | .28 | Inter-Quartile Range .15 to .36 | mls/kg/min | |
| Oxygen Consumption | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | .27 | Inter-Quartile Range .19 to .35 | mls/kg/min | |
| Heart Rate | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 91 | Inter-Quartile Range 84 to 103 | beats per minute | |
| Heart Rate | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 93 | Inter-Quartile Range 87 to 102 | beats per minute |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Intervention (5 Min of Drug) | STARTED | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 12 | |
| First Intervention (5 Min of Drug) | STARTED | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 12 | |
| First Intervention (5 Min of Drug) | COMPLETED | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 12 | |
| First Intervention (5 Min of Drug) | COMPLETED | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 12 | |
| First Intervention (5 Min of Drug) | NOT COMPLETED | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 0 | |
| First Intervention (5 Min of Drug) | NOT COMPLETED | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 0 | |
| Washout (4 Hours) | STARTED | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 12 | |
| Washout (4 Hours) | STARTED | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 12 | |
| Washout (4 Hours) | COMPLETED | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 12 | |
| Washout (4 Hours) | COMPLETED | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 12 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 0 | 12 |
| Total, all-cause mortality | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 0 | 12 |
| Total, other adverse events | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 0 | 12 |
| Total, other adverse events | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 0 | 12 |
| Total, serious adverse events | Albuterol 5 mg First, Then Levalbuterol 2.5 mg | 0 | 12 |
| Total, serious adverse events | Levalbuterol 2.5 mg First, Then Albuterol 5 mg | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Albuterol 5 mg First, Then Levalbuterol 2.5 mg vs Levalbuterol 2.5 mg First, Then Albuterol 5 mg: deaths from any cause | Trial comparisons |
| Albuterol 5 mg First, Then Levalbuterol 2.5 mg vs Levalbuterol 2.5 mg First, Then Albuterol 5 mg: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02802111
GET https://conductscience.org/api/trials/v1/NCT02802111/registered